Oncolytics Biotech Inc. has collaborative agreements with the National Cancer Institute,[REF] the University of Leeds,[REF] and the Cancer Therapy & Research Centre at the University of Texas Health Science Center in San Antonio[REF] to conduct multiple phase I/II and phase II trials in the United States and United Kingdom.
On September 2, 2010, the Company announced that the Gynecologic Oncology Group (GOG) would be pursuing a new phase II study of Reolysin in combination with weekly paclitaxel in patients with persistent or recurrent ovarian, fallopian, or primary peritoneal cancer [REF].